Response to antipsychotic medication: the doctor's and the consumer's view.
The subjective response to antipsychotic medication was systematically evaluated in two samples of schizophrenic patients, one treated with haloperidol, the other with thiothixene. For both groups, a dysphoric response to the first dose was found to be a powerful predictor of noncompliance. A persisting dysphoric response was associated with a poor clinical outcome. Dysphoric responses were powerfully associated with akathisia. Patients' subjective responses were consistent throughout therapy, and there was moderate agreement between the patients' evaluation of the medication and the staff's ratings of improvement. The authors suggest that the subjective response to antipsychotic medication should not be dismissed and that dysphoric responses should be acknowledged.
D000328:Adult; D017109:Akathisia, Drug-Induced; D001291:Attitude of Health Personnel; D001294:Attitude to Health; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000523:psychology; D005260:Female; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010349:Patient Compliance; D011336:Probability; D011569:Psychiatric Status Rating Scales; D011595:Psychomotor Agitation / Q000523:psychology; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013888:Thiothixene / Q000009:adverse effects* / Q000627:therapeutic use
D013888:Thiothixene; D006220:Haloperidol